Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281689 | 0.90 | ACHE (0.50) | ACHEDRD2DRD1HTR1AHTR2A | |
| SCHEMBL6330755 | 0.90 | ACHE (0.50) | ACHEDRD2DRD1HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL3171185 | 0.88 | ACHE (0.49) | ACHEDRD2DRD1HTR1AHTR2A | |
| SCHEMBL14606247 | 0.86 | DRD2 (0.42) | ACHEDRD2DRD1ESR1ESR2 | |
| SCHEMBL7865743 | 0.84 | ACHE (0.43) | ACHEDRD2HTR1AHTR2AKCNH2 | |
| Hydrochloric Acid SCHEMBL7875148 | 0.82 | ACHE (0.45) | ACHEDRD2HTR1AHTR2AKCNH2 | |
| SCHEMBL8307806 | 0.79 | DRD2 (0.48) | DRD2DRD1ESR1ESR2CYP2D6 | |
| SCHEMBL27827581 | 0.78 | ACHE (0.42) | ACHEDRD2HTR1AHTR2AKCNH2 | |
| SCHEMBL19978162 | 0.78 | HTR1A (0.43) | ACHEDRD2HTR1AHTR2AKCNH2 | |
| SCHEMBL7369494 | 0.77 | ACHE (0.39) | ACHEDRD2HTR1AHTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | ACHE 2683/4885DRD2 327/4885DRD1 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.